Back to Browse Journals » International Journal of Nanomedicine » Volume 2 » Issue 4

Nano-liposomal dry powder inhaler of tacrolimus: Preparation, characterization, and pulmonary pharmacokinetics

Authors Mahavir Chougule, Bijay Padhi, Ambikanandan Misra

Published 15 January 2008 Volume 2007:2(4) Pages 675—688

Mahavir Chougule, Bijay Padhi, Ambikanandan Misra

TIFAC-CORE in NDDS, Pharmacy Department, Faculty of Technology and Engineering, The Maharaja Sayajirao University of Baroda, Kalabhavan, Vadodara, India

Abstract: The studies were undertaken to evaluate feasibility of pulmonary delivery of liposomaly encapsulated tacrolimus dry powder inhaler for prolonged drug retention in lungs as rescue therapy to prevent refractory rejection of lungs after transplantation. Tacrolimus encapsulated liposomes were prepared by thin film evaporation technique and liposomal dispersion was passed through high pressure homogenizer. Tacrolimus nano-liposomes (NLs) were separated by centrifugation and characterized. NLs were dispersed in phosphate buffer saline (PBS) pH 7.4 containing different additives like lactose, sucrose, and trehalose, and L-leucine as antiadherent. The dispersion was spray dried and spray dried powders were characterized. In vitro and in vivo pulmonary deposition was performed using Andersen Cascade Impactor and intratracheal instillation in rats respectively. NLs were found to have average size of 140 nm, 96% ± 1.5% drug entrapment, and zeta potential of 1.107 mV. Trehalose based formulation was found to have low density, good flowability, particle size of 9.46 ± 0.8 µm, maximum fine particle fraction (FPF) of 71.1 ± 2.5%, mean mass aerodynamic diameter (MMAD) 2.2 ± 0.1 µm, and geometric standard deviation (GSD) 1.7 ± 0.2. Developed formulations were found to have in vitro prolonged drug release up to 18 hours, following Higuchi’s Controlled Release model. In vivo studies revealed maximal residence of tacrolimus within lungs of 24 hours, suggesting slow clearance from the lungs. The investigation provides a practical approach for direct delivery of tacrolimus encapsulated in NLs for controlled and prolonged retention at the site of action. It may play a promising role as rescue therapy in reducing the risk of acute rejection and chronic rejection.

Keywords: lung transplant rejection, tacrolimus, nano-liposomes, spray drying, dry powder inhaler

 

Download Article [PDF] 

Readers of this article also read:

Beta-blockers and health-related quality of life in patients with peripheral arterial disease and COPD

Yvette RBM van Gestel, Sanne E Hoeks, Don D Sin, Henk Stam, Frans W Mertens, Jeroen J Bax, Ron T van Domburg, Don Poldermans

International Journal of Chronic Obstructive Pulmonary Disease 2009, 4:177-183

Published Date: 8 May 2009

Determinants and predictors of the cost of COPD in primary care: A Spanish perspective

Javier de Miguel Diez, Pilar Carrasco Garrido, Marta García Carballo, Angel Gil de Miguel, Javier Rejas Gutierrez, et al

International Journal of Chronic Obstructive Pulmonary Disease 2008, 3:701-712

Published Date: 5 December 2008

Assessment of acceptability and ease of use of atovaquone/proguanil medication in subjects undergoing malaria prophylaxis

V Nicosia, Giorgio Colombo, M Consentino, S Di Matteo, F Mika, et al

Therapeutics and Clinical Risk Management 2008, 4:1105-1110

Published Date: 10 October 2008

Silent myocardial infarction in women with type II diabetes mellitus and microalbuminuria

Elmir Omerovic, Gerhard Brohall, Markus Müller, Truls Råmunddal, Göran Matejka, et al

Therapeutics and Clinical Risk Management 2008, 4:705-711

Published Date: 8 August 2008

Formoterol in the management of chronic obstructive pulmonary disease

Paschalis Steiropoulos, Argyris Tzouvelekis, Demosthenes Bouros

International Journal of Chronic Obstructive Pulmonary Disease 2008, 3:205-215

Published Date: 6 June 2008

Moderate and severe plaque psoriasis: cost-of-illness study in Italy

GL Colombo, GF Altomare, K Peris, P Martini, G Quarta

Therapeutics and Clinical Risk Management 2008, 4:559-568

Published Date: 11 April 2008

Review of photodynamic therapy in actinic keratosis and basal cell carcinoma

Marica B Ericson, Ann-Marie Wennberg, Olle Larkö

Therapeutics and Clinical Risk Management 2008, 4:1-9

Published Date: 8 February 2008

Review of tenofovir-emtricitabine

Saba Woldemichael Masho, Cun-Lin Wang, Daniel E Nixon

Therapeutics and Clinical Risk Management 2007, 3:1097-1104

Published Date: 15 January 2008

Levobetaxolol hydrochloride: a review of its pharmacology and use in the treatment of chronic open-angle glaucoma and ocular hypertension

Luciano Quaranta, Raffaele Turano, Teodoro Pizzolante

Clinical Ophthalmology 2007, 1:93-97

Published Date: 15 September 2007